ClinicalTrials.gg
CompletedNCT04545515Updated May 8, 2024Results posted

A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes

A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 34 sites in 10 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.

Enrollment
12th of 23
120 · median 120
Started
2021
with 2 others
Phase 3
19 of 23
none open now
Registered
12th of 23
by date
Lead sponsor
20 of 23
Vertex Pharmaceuticals Incorporated

Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 12th largest by enrollment, is one of 3 that started in 2021, is one of 19 in phase 3, and was the 12th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About elexacaftor

elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing elexacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

The study evaluates the long-term safety and efficacy of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) triple combination (TC) in participants with CF who are 6 years of age and older with F/MF genotypes.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Completed study drug treatment in parent study (VX19-445-116, NCT04353817), or had study drug interruption(s) in parent study but completed study visits up to the last scheduled visit of the treatment period in the parent study

Key Exclusion Criteria:

  • History of study drug intolerance in the parent study

Other protocol defined Inclusion/Exclusion criteria may apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    ELX/TEZ/IVA

    Participants 6 to less than \<12 year of age and weighing \<30 kilogram (kg) at Day 1 received ELX 100 milligram (mg)/TEZ 50 mg /IVA 75 mg as fixed dose combination (FDC) tablets in the morning and IVA as mono tablet in the evening and those weighing more than or equal to (≥) 30 kg at Day 1 received ELX 200 mg/TEZ 100 mg /IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 96 weeks. Doses were adjusted upward with subsequent changes in weight. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 96 weeks.

    Drug: ELX/TEZ/IVA · Drug: IVA

Interventions

  • DrugELX/TEZ/IVA

    Drug pages: Elexacaftor · Tezacaftor · Ivacaftor

    Fixed dose combination (FDC) tablets for oral administration.

    Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor

  • DrugIVA

    Tablet for oral administration.

    Also known as: VX-770, ivacaftor

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Baseline up to Week 100

Secondary outcomes

  1. Absolute Change From Parent Study Baseline in Sweat Chloride (SwCl)

    Sweat samples were collected using an approved collection device.

    Time frame: From Parent Study Baseline to Week 96

  2. Absolute Change From Parent Study Baseline in Lung Clearance Index 2.5 (LCI2.5)

    The LCI2.5 index is the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting values and is calculated by dividing the sum of exhaled tidal breaths (cumulative exhaled volume (CEV)) by simultaneously measured functional residual capacity (FRC). An LCI of 7.5 and below is normal; values greater than 7.5 are abnormal. LCI is able to detect abnormalities in lung function earlier than more traditional modalities such as spirometry.

    Time frame: From Parent Study Baseline to Week 96

07

Results

Posted May 8, 2024

Participant flow

Participant flow — Overall Study
MilestoneELX/TEZ/IVA
Started120
Placebo-elx/tez/iva61
Elx/tez/iva-elx/tez/iva59
Completed110
Not completed10
Withdrew: Adverse event1
Withdrew: Withdrawal of consent (not due to ae)2
Withdrew: Commercial drug is available for participant7

Outcome measures

PrimarySafety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
From Baseline up to Week 100
Reported as:
Count of participants · Participants
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsELX/TEZ/IVA
Participants with TEAEs118
Participants with SAEs13
SecondaryAbsolute Change From Parent Study Baseline in Sweat Chloride (SwCl)

Sweat samples were collected using an approved collection device.

Time frame:
From Parent Study Baseline to Week 96
Reported as:
Least squares mean · millimole per liter (mmol/L)
Absolute Change From Parent Study Baseline in Sweat Chloride (SwCl)
millimole per liter (mmol/L)ELX/TEZ/IVA
Placebo (Parent study)-ELX/TEZ/IVA (Current study)-57.3 ± 2.2
ELX/TEZ/IVA (Parent study)-ELX/TEZ/IVA (Current study)-57.5 ± 2.3
SecondaryAbsolute Change From Parent Study Baseline in Lung Clearance Index 2.5 (LCI2.5)

The LCI2.5 index is the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting values and is calculated by dividing the sum of exhaled tidal breaths (cumulative exhaled volume (CEV)) by simultaneously measured functional residual capacity (FRC). An LCI of 7.5 and below is normal; values greater than 7.5 are abnormal. LCI is able to detect abnormalities in lung function earlier than more traditional modalities such as spirometry.

Time frame:
From Parent Study Baseline to Week 96
Reported as:
Least squares mean · Index
Absolute Change From Parent Study Baseline in Lung Clearance Index 2.5 (LCI2.5)
IndexELX/TEZ/IVA
Placebo (Parent study)-ELX/TEZ/IVA (Current study)-1.74 ± 0.18
ELX/TEZ/IVA (Parent study)-ELX/TEZ/IVA (Current study)-2.35 ± 0.19

Adverse events

Collected over Day 1 up to Week 100. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ELX/TEZ/IVA0/120 (0%)13/120 (10.8%)118/120 (98.3%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventELX/TEZ/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations2/120
ConstipationGastrointestinal disorders1/120
EnteritisGastrointestinal disorders1/120
Ileus paralyticGastrointestinal disorders1/120
Intestinal obstructionGastrointestinal disorders1/120
SteatorrhoeaGastrointestinal disorders1/120
General physical health deteriorationGeneral disorders1/120
Bacterial disease carrierInfections and infestations1/120
Pneumonia pseudomonalInfections and infestations1/120
Pneumonia staphylococcalInfections and infestations1/120
Most frequent other events
Showing 10 of 33
Most frequent other events
EventELX/TEZ/IVA
COVID-19Infections and infestations70/120
CoughRespiratory, thoracic and mediastinal disorders62/120
NasopharyngitisInfections and infestations54/120
PyrexiaGeneral disorders48/120
HeadacheNervous system disorders45/120
Upper respiratory tract infectionInfections and infestations37/120
Oropharyngeal painRespiratory, thoracic and mediastinal disorders32/120
RhinitisInfections and infestations29/120
Abdominal painGastrointestinal disorders27/120
VomitingGastrointestinal disorders24/120

Baseline characteristics

Baseline data for the long-term safety analysis is based on the parent study baseline, which is defined as the most recent non-missing measurement collected before the first dose of study drug in the treatment period of parent study.

Age, Continuous
Age, Continuous(years)ELX/TEZ/IVA
Mean9.1 ± 1.7
Sex: Female, Male
Sex: Female, Male(Participants)ELX/TEZ/IVA
Female69
Male51
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ELX/TEZ/IVA
Hispanic or Latino1
Not Hispanic or Latino90
Not collected per local regulations29
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ELX/TEZ/IVA
White87
Black or African American1
Asian1
American Indian or Alaska Native1
Other1
Not collected per local Regulations28
Multiracial1
08

Study locations

34 sites
  • Telethon Kids Institute
    Nedlands, Australia
  • Queensland Children's Hospital
    South Brisbane, Australia
  • The Children's Hospital at Westmead
    Westmead, Australia
  • McGill University Health Centre, Glen Site, Montreal Children's Hospital
    Montreal, Canada
  • The Hospital for Sick Children
    Toronto, Canada
  • British Columbia Children's Hospital
    Vancouver, Canada
  • Juliane Marie Center, Rigshospitalet
    Copenhagen, Denmark
  • Groupe Hospitaler Pellegrin, CHU De Bordeaux
    Bordeaux cedex, France
  • CHU Lyon - Hopital Femme Mere-Enfant
    Bron Cedex, France
  • Hopital Necker, Enfants Malades
    Paris Cedex 15, France
  • Hopital Robert Debre
    Paris, France
  • Centre de Perharidy
    Roscoff cedex, France
  • Charite Paediatric Pulmonology Department
    Berlin, Germany
  • Universitatsklinikum Essen (AoR), Kinderklinik III, Abt. fur Pneumologie
    Essen, Germany
  • Johann Wolfgang Goethe University
    Frankfurt, Germany
  • Justus-Liebig-Universität Gießen Zentrum fur Kinderheilkunde und Jugendmedizin
    Gießen, Germany
  • Medizinische Hochschule Hannover
    Hannover, Germany
  • Universitaetsklinikum Heidelberg, Zenter fuer Kinder-und Jugendmedizin
    Heidelberg, Germany
  • Universitaetsklinkum Koeln, CF-Studienzentrum
    Koeln, Germany
  • Hadassah University Hospital Mount Scopus
    Jerusalem, Israel
  • Schneider Children's Medical Center of Israel
    Petach Tikvah, Israel
  • Universitair Medisch Centrum Groningen
    Groningen, Netherlands
  • Erasmus Medical Center / Sophia Children's Hospital
    Rotterdam, Netherlands
  • Hospital Universitari Vall d Hebron
    Barcelona, Spain
  • Hospital Virgen de la Arrixaca
    Murcia, Spain
  • Inselspital - Universitaetsspital Bern
    Bern, Switzerland
  • Kinderspital Zuerich
    Zurich, Switzerland
  • University Hospitals Bristol and Weston NHS Foundation Trust, Bristol Royal Hospital
    Bristol, United Kingdom
  • Children's Hospital of Wales
    Cardiff, United Kingdom
  • Royal Hospital for Sick Children
    Edinburgh, United Kingdom
  • Alder Hey Children's NHS Foundation Trust
    Liverpool, United Kingdom
  • Great Ormond Street Hospital for Sick Children
    London, United Kingdom
  • Royal Brompton & Harefield NHS Foundation Trust, Royal Brompton Hospital
    London, United Kingdom
  • Southampton General Hospital
    Southampton, United Kingdom
09

References and documents

Publications

  • Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. PubMed 33331662 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Mar 2023, 26 months.

Results were first posted in May 2024, 1 year 1 month after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 26 months is close to that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2020
First posted
Sep 11, 2020
StartActual
Jan 11, 2021
Primary completionActual
Mar 24, 2023
CompletionActual
Mar 24, 2023
Results first posted
May 8, 2024
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04545515
Responsible party
Sponsor
First posted
Sep 11, 2020
Start date
Jan 11, 2021
Primary completion
Mar 24, 2023
Completion
Mar 24, 2023
Results posted
May 8, 2024
Last update
May 8, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor

Start the discussion